» Articles » PMID: 25296972

Novel Robust Biomarkers for Human Bladder Cancer Based on Activation of Intracellular Signaling Pathways

Abstract

We recently proposed a new bioinformatic algorithm called OncoFinder for quantifying the activation of intracellular signaling pathways. It was proved advantageous for minimizing errors of high-throughput gene expression analyses and showed strong potential for identifying new biomarkers. Here, for the first time, we applied OncoFinder for normal and cancerous tissues of the human bladder to identify biomarkers of bladder cancer. Using Illumina HT12v4 microarrays, we profiled gene expression in 17 cancer and seven non-cancerous bladder tissue samples. These experiments were done in two independent laboratories located in Russia and Canada. We calculated pathway activation strength values for the investigated transcriptomes and identified signaling pathways that were regulated differently in bladder cancer (BC) tissues compared with normal controls. We found, for both experimental datasets, 44 signaling pathways that serve as excellent new biomarkers of BC, supported by high area under the curve (AUC) values. We conclude that the OncoFinder approach is highly efficient in finding new biomarkers for cancer. These markers are mathematical functions involving multiple gene products, which distinguishes them from "traditional" expression biomarkers that only assess concentrations of single genes.

Citing Articles

Bioinformatic and clinical experimental assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new combined and individual survival biomarkers outperforming promoter methylation.

Modestov A, Zolotovskaia M, Suntsova M, Zakharova G, Seryakov A, Jovcevska I Ther Adv Med Oncol. 2024; 16:17588359241292269.

PMID: 39525666 PMC: 11544758. DOI: 10.1177/17588359241292269.


Algorithmically Reconstructed Molecular Pathways as the New Generation of Prognostic Molecular Biomarkers in Human Solid Cancers.

Zolotovskaia M, Kovalenko M, Pugacheva P, Tkachev V, Simonov A, Sorokin M Proteomes. 2023; 11(3).

PMID: 37755705 PMC: 10535530. DOI: 10.3390/proteomes11030026.


Effects and Mechanisms of Kaempferol in the Management of Cancers through Modulation of Inflammation and Signal Transduction Pathways.

Almatroudi A, Allemailem K, Alwanian W, Alharbi B, Alrumaihi F, Khan A Int J Mol Sci. 2023; 24(10).

PMID: 37239974 PMC: 10218111. DOI: 10.3390/ijms24108630.


Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data.

Sorokin M, Zolotovskaia M, Nikitin D, Suntsova M, Poddubskaya E, Glusker A BMC Cancer. 2022; 22(1):1113.

PMID: 36316649 PMC: 9623986. DOI: 10.1186/s12885-022-10177-3.


Exploring the recent trends in perturbing the cellular signaling pathways in cancer by natural products.

Rahman M, Sarker M, Tumpa M, Yamin M, Islam T, Park M Front Pharmacol. 2022; 13:950109.

PMID: 36160435 PMC: 9498834. DOI: 10.3389/fphar.2022.950109.


References
1.
Kim D, Gazourian L, Quadri S, Romieu-Mourez R, Sherr D, Sonenshein G . The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene. 2000; 19(48):5498-506. DOI: 10.1038/sj.onc.1203945. View

2.
Zhavoronkov A, Buzdin A, Garazha A, Borisov N, Moskalev A . Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front Genet. 2014; 5:49. PMC: 3940060. DOI: 10.3389/fgene.2014.00049. View

3.
Geiduschek E, Kassavetis G . Transcription: adjusting to adversity by regulating RNA polymerase. Curr Biol. 2006; 16(19):R849-51. DOI: 10.1016/j.cub.2006.08.071. View

4.
Wicks S, Lui S, Abdel-Wahab N, Mason R, Chantry A . Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol Cell Biol. 2000; 20(21):8103-11. PMC: 86420. DOI: 10.1128/MCB.20.21.8103-8111.2000. View

5.
Sanchez-Carbayo M, Cordon-Cardo C . Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer. 2003; 89(12):2172-7. PMC: 2395269. DOI: 10.1038/sj.bjc.6601406. View